A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver

By sjmartinez • December 11, 2024

Perry AS, Hadad N, Chatterjee E, Jimenez-Ramos M, Farber-Eger E, Roshani R, Stolze LK, Betti MJ, Zhao S, Huang S, Martens L, Kendall TJ, Thone T, Amancherla K, Bailin S, Gabriel CL, Koethe J, Carr JJ, Terry JG, Vaitinadin NS, Freedman JE, Tanriverdi K, Alsop E, Van Keuren-Jensen K, Sauld JFK, Mahajan G, Khan SS, Colangelo L, Nayor M, Fisher-Hoch S, McCormick JB, North KE, Below JE, Wells QS, Abel ED, Kalhan R, Scott C, Guilliams M, Gamazon ER, Fallowfield JA, Banovich NE, Das S, Shah R. A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver. Cell Rep Med. 2024 Dec 4:101871. doi: 10.1016/j.xcrm.2024.101871. Epub ahead of print. PMID: 39657669.

Tags: diabetes, Endocrinology, liver-on-a-chip, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, proteomics, Publications

A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors

Mogar N, Zhang D, Heaney AP. A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors. Int J Mol Sci. 2025 Jun 19;26(12):5898.[...]

Metabolic Messengers: oestradiol

Hevener AL, Correa SM. Metabolic Messengers: oestradiol. Nat Metab. 2025 Jun;7(6):1114-1122. doi: 10.1038/s42255-025-01317-7. Epub 2025 Jun 24. PMID: 40562968.

Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in[...]